5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid
C28H26ClF3N2O5 — CID 146057895
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid
5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid (PubChem CID 146057895) has the molecular formula C28H26ClF3N2O5 and a molecular weight of 562.97 g/mol. Its IUPAC name is 5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid.
Molecular Properties
| Compound Name | 5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid |
|---|---|
| PubChem CID | 146057895 |
| Molecular Formula | C28H26ClF3N2O5 |
| Molecular Weight | 562.97 g/mol |
| Exact Mass | 562.15 |
| IUPAC Name | 5-(4-benzylpiperidin-1-yl)-2-[(2-chlorobenzoyl)amino]benzoic acid;2,2,2-trifluoroacetic acid |
| SMILES | O=C(Nc1ccc(N2CCC(Cc3ccccc3)CC2)cc1C(=O)O)c1ccccc1Cl.O=C(O)C(F)(F)F |
| InChI | InChI=1S/C26H25ClN2O3.C2HF3O2/c27-23-9-5-4-8-21(23)25(30)28-24-11-10-20(17-22(24)26(31)32)29-14-12-19(13-15-29)16-18-6-2-1-3-7-18;3-2(4,5)1(6)7/h1-11,17,19H,12-16H2,(H,28,30)(H,31,32);(H,6,7) |
| InChIKey | TWPIFGKQLWQBTC-UHFFFAOYSA-N |
| XLogP | 6.38 |
| TPSA | 106.94 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 39 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 562.97 |
| LogP ≤ 5 | 6.38 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 146057895 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.